Boosting natural detoxification pathways in the body to reduce cellular oxidative stress Blog Post

Promoting innate detoxification mechanisms in the body and discovering which supplements increase the efficacy of those biochemical pathways could be an efficient strategy to reduce the cellular oxidative stress and protect our health, according to an article published in the journal Food Chemistry, by the researchers Rafael Franco, from the Institute of Biomedicine of the University of Barcelona at the Barcelona Science Park and Eva Martínez Pinilla, from the Institute of Neurosciences of Asturias (INEUROPA) and the University of Oviedo.

 

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain Blog Post

Esteve at the Barcelona Science Park co-leads the NGN-PET consortium, that unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia for the development of novel, more efficacious treatments for chronic pain of neuropathic origin. NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry.

 

Chemotargets and the Josep Carreras Leukemia Research Institute sign collaboration agreement Blog Post

The Josep Carreras Leukemia Research Institute (IJC) announced today that it has entered into a collaboration agreement with the IMIM’s spin-off Chemotargets, located at the Barcelona Science Park.  The aim of the collaboration is to further understand the mechanism of action of some active hits in leukemia discovered at IJC, and exploit this information to identify new chemical entities with improved pharmacology and safety profiles using Chemotargets’ precision modeling platform. 

 

Tomàs Marquès-Bonet awarded by the Howard Hughes Medical Institute Blog Post

Researcher Tomàs Marquès-Bonet, director of the Institute for Evolutionary Biology (IBE), and leader of the Comparative Genomics group at CNAG-CRG at the Barcelona Science Park, has been awarded the International Early Career Award by the Howard Hughes Medical Institute (HHMI, USA). He will receive $ 650,000 spread over five years, starting in September 2017. A total of 1,600 researchers from around the world attended the call, of which only 41 were selected. To date, only 5 investigators in Spain have received this recognition.

 

IBEC is bioprinting partner in major 3D printing hub in Catalonia Blog Post

The Institute for Bioengineering of Catalonia (IBEC), based at Barcelona Science Park, is to be part of a the Global 3D Printing Hub, a 3D printing infrastructure in Catalonia, which will receive up to 28 million euros from the Generalitat by 2020 to consolidate Catalonia as a world leader in 3D printing, one of the key technologies in industry 4.0. The Global 3D Printing Hub will be headquartered in 10.000m2 of the Campus Diagonal Besòs in Barcelona.

 

A genome-editing strategy to study cancer stem cells in human tumours Blog Post

In EMBO Molecular Medicine, IRB Barcelona scientists at PCB report a technique based on a combination of CRISPR/Cas9 genome editing and patient-derived tumour organoids that allows the study of cell heterogeneity in human tumours.The novel approach was used to examine the behaviour of colorectal cancer stem cells by tracing specific marker genes.

 

A study reveals the biological changes in breast cancer between the primary tumour and metastases Blog Post

Researchers at  the Institute for Research in Biomedicine (IRB Barcelona) and the August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and have described that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes. The work – published in Cancer Research– has also shown that between the initial tumour and the metastasis the subtype of breast cancer can change in up to 40% of cases.